Manassas, VA, United States of America

Dana Austin

This inventor holds 1 USPTO granted patent and 6 published patent applications and 1 EPO patent. Top assignee: Serpin Pharma, LLC. Active years: 2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dana Austin. Retrieved from https://idiyas.com/inventor/dana-austin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dana Austin: Innovator in Peptide Technology

Introduction

Dana Austin is a notable inventor based in Manassas, Virginia. He has made significant contributions to the field of peptide technology, particularly in the development of SERPIN peptides. His work focuses on innovative methods for treating conditions associated with LRP1 mediation.

Latest Patents

Dana Austin holds one patent titled "Peptides and methods of using the same." This patent discloses SERPIN peptides, along with their analogues and derivatives, and outlines their uses in treating various medical conditions.

Career Highlights

Austin is associated with Serpin Pharma, LLC, where he applies his expertise in peptide research. His work at the company has positioned him as a key player in the advancement of therapeutic solutions.

Collaborations

One of his notable coworkers is Cohava Gelber, who contributes to the innovative environment at Serpin Pharma, LLC.

Conclusion

Dana Austin's contributions to peptide technology exemplify the impact of innovation in the medical field. His work continues to pave the way for new treatments and advancements in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…